Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis.

Détails

Ressource 1Télécharger: 32714935_BIB_D31A60BC3E59.pdf (1608.69 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_D31A60BC3E59
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis.
Périodique
Frontiers in medicine
Auteur(s)
Dimitriou F., Schanz U., Nair G., Kimeswenger S., Brüggen M.C., Hoetzenecker W., French L.E., Dummer R., Cozzio A., Guenova E.
ISSN
2296-858X (Print)
ISSN-L
2296-858X
Statut éditorial
Publié
Date de publication
2020
Peer-reviewed
Oui
Volume
7
Pages
290
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been proposed as curative approach for advanced cutaneous T-cell lymphomas (CTCL). Currently, there is no established consensus for the management of disease relapse after alloHSCT. Results: Ten patients, previously treated with multiple lines of systemic treatment, received alloHSCT. Six patients had achieved partial response (PR, N = 5) and complete response (CR, N = 1) prior to HSCT. Post-HSCT, seven patients (N = 7) relapsed after a median time of 3.3 months (0.5-7.4 months) and were subsequently treated with radiotherapy (RT, N = 1), RT and adoptive T-cell transfer with EBV specific cells (N = 1), R-CHOP (N = 1) and interferon alpha-2a combined either with donor lymphocyte infusion (N = 1) or with brentuximab-vedotin (N = 1). One patient (N = 1) achieved PR only after reducing the immunosuppression. Two patients relapsed again and received interferon alpha-2a and brentuximab-vedotin, respectively. After a median follow-up time of 12.6 months (3.5-73.7 months) six patients were alive (60%) and four had deceased, three (N = 3) due to CTCL and one (N = 1) due to GVHD. Conclusion: Disease relapse after alloHSCT can be controlled with available treatments. For most patients who ultimately relapsed, reduction of immunosuppression and interferon alpha-2a either administered alone or in combination with another systemic agent were preferred. Although interferon alpha-2a, similarly to immunosuppression reduction, may be beneficial for the achievement of graft-vs.-lymphoma effect, the risk of simultaneous worsening of GVHD must be carefully evaluated and taken into consideration.
Mots-clé
Sézary syndrome, allogeneic stem cell transplantation, cutaneous T-cell lymphoma, interferon alpha-2a, mycosis fungoides
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/08/2020 10:10
Dernière modification de la notice
15/01/2021 7:12
Données d'usage